Key facts
- This page summarizes Barbara Kosacz's Form 4 filing for Kronos Bio, Inc. (KRON).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Feb 2023, 15:19.
Barbara Kosacz - 15 Feb 2023 Form 4 Insider Report for Kronos Bio, Inc. (KRON)
- Reporting relationship
- COO & General Counsel
- Issuer ticker
- KRON
- Reported as of
- 15 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Feb 2023, 15:19:21 UTC
- Prior SEC filing
- 27 Jul 2022
- Next SEC filing
- 19 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Allison Frisbee, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Barbara Kosacz filed Form 4 for Kronos Bio, Inc. (KRON) on 17 Feb 2023.
Change
- Previous filing in this sequence was filed on 27 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KRON
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +138,911
- Change %
- +17%
- Price
- $0.000000
- Shares after
- 939,642
- Date
- 15 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KRON
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +208,367
- Change %
- Price
- $0.000000
- Shares after
- 208,367
- Date
- 15 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 208,367
- Exercise price
- $2.09
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes an aggregate of 9,107 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on the following dates: 1,878 shares on June 30, 2021, 753 shares on December 31, 2021 and 6,476 shares on December 30, 2022.
Footnote F2
1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.